SEC 13F Intelligence

Managers / Q4 2022 · view latest →

Sio Capital Management, LLC

CIK 0001482416 · 600 THIRD AVENUE, 2ND FLOOR, NEW YORK, NY, 10016 · 212-601-9792

Reported Value
$270M
Q4 2022
Positions
47
Filings on Record
30
2019–present window
Filed
Feb 13, 2023
original filing

Summary

Sio Capital Management, LLC reported $270M in U.S.-listed holdings across 47 positions for Q4 2022.

Its largest position, Medicus Sciences Acquisition, represents 8.7% of the portfolio.

Compared with Q3 2022, the fund opened 14 new positions and exited 18.

Portfolio Metrics

Turnover
+44.2%
vs prior filed quarter
Top-10 Concentration
+50.5%
share of reported value
Largest Position
+8.7%
Medicus Sciences Acquisition
New / Exited
14 / 18
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $275MQ4 ’18Q1 ’19: $370MQ2 ’19: $415MQ3 ’19: $310MQ4 ’19: $420MQ4 ’19Q1 ’20: $298MQ2 ’20: $343MQ3 ’20: $505MQ4 ’20: $489MQ4 ’20Q1 ’21: $493MQ2 ’21: $402MQ3 ’21: $314MQ4 ’21: $332MQ4 ’21Q1 ’22: $302MQ2 ’22: $266MQ3 ’22: $315MQ4 ’22: $270MQ4 ’22Q1 ’23: $202MQ2 ’23: $393MQ3 ’23: $323MQ4 ’23: $439MQ4 ’23Q1 ’24: $336MQ2 ’24: $370MQ3 ’24: $252MQ4 ’24: $355MQ4 ’24Q1 ’25: $336MQ2 ’25: $262MQ3 ’25: $395MQ4 ’25: $636MQ4 ’25Q1 ’26: $697Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 49.4%Other: 43.1%ADR: 7.5%
  • Common Stock · 49.4% · $134M
  • Other · 43.1% · $116M
  • ADR · 7.5% · $20M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
DGXQUEST DIAGNOSTICS INCNEW+92.0K92.0K+$14M$14M
MEDTRONIC PLCNEW+128.0K128.0K+$10M$10M
STAASTAAR SURGICAL CONEW+157.1K157.1K+$8M$8M
ICON PLCNEW+34.0K34.0K+$7M$7M
AVTRAVANTOR INCNEW+250.0K250.0K+$5M$5M
HSKAEURHESKA CORPNEW+84.3K84.3K+$5M$5M
PTGXPROTAGONIST THERAPEUTICS INCNEW+434.6K434.6K+$5M$5M
NVV1NOVAVAX INCNEW+340.0K340.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

41 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MEDICUS SCIENCES ACQUISITIONCL A SHS8.65%$23M2.32M
2BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS7.48%$20M683.4K
3CICIGNA CORPhistory →COM6.45%$17M52.6K
4OGNORGANON & COhistory →COMMON STOCK6.07%$16M587.8K
5UTHUNITED THERAPEUTICS CORPhistory →COM5.65%$15M55.0K
6ABGAMERISOURCEBERGEN CORPhistory →COM5.17%$14M84.4K
7MEDTRONIC PLCSHS3.68%$10M128.0K
8STAASTAAR SURGICAL COhistory →COM PAR $0.012.82%$8M157.1K
9ICON PLCSHS2.44%$7M34.0K
10INGNINOGEN INChistory →COM2.09%$6M286.7K
11AVTRAVANTOR INChistory →COM1.95%$5M250.0K
12HSKAEURHESKA CORPhistory →COM RESTRC NEW1.94%$5M84.3K
13PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.75%$5M434.6K
14NVV1NOVAVAX INChistory →COM NEW1.29%$3M340.0K
15CYMABAY THERAPEUTICS INCCOM1.29%$3M555.6K
16PHARVARIS NVCOM1.19%$3M285.0K
17MACKEURMERRIMACK PHARMACEUTICALS INChistory →COM NEW1.06%$3M250.0K
18HEALTH SCIENCES ACQUISITIONS CORP 2ORD SHS0.92%$2M250.0K
19EUCRATES BIOMEDICAL ACQUISITION CORP.UNIT 10/23/20270.92%$2M248.7K
20CTIC1USDCTI BIOPHARMA CORPCOM0.73%$2M330.0K
21ASNSUSDX4 PHARMACEUTICALS INCCOM0.67%$2M1.83M
22MODULAR MEDICAL INCCOM NEW0.51%$1M689.4K
23MERUS NVCOM0.50%$1M88.0K
24AGLEUSDAEGLEA BIO THERAPEUTICS INCCOM0.50%$1M3.00M
25YB4PSAVARA INCCOM0.50%$1M866.4K
26IDYAIDEAYA BIOSCIENCES INCCOM0.47%$1M70.0K
27TYRATYRA BIOSCIENCES INCCOM0.43%$1M152.2K
28MBRXEURMOLECULIN BIOTECH INCCOM0.41%$1M1.04M
29VNDAVANDA PHARMACEUTICALS INCCOM0.37%$1M136.3K
30RLMDRELMADA THERAPEUTICS INCCOM0.30%$821,895235.5K
31FUSION PHARMACEUTICALS INCCOM0.30%$820,411260.4K
32CONNECT BIOPHARMA HOLDINGS LTDADS0.19%$518,665597.7K
33SIENUSDSIENTRA INCCOM0.19%$517,3952.55M
34ASLAN PHARMACEUTICALS LTDADS0.17%$457,4731.27M
35ELEVATION ONCOLOGY INCCOM0.13%$341,744359.7K
36NXTCEURNEXTCURE INCCOM0.07%$183,300130.0K
37CAREMAX INCCOM CL A · *W EXP 06/08/2020.04%$118,89743.5K
38VINCERX PHARMA INCCOM NEW0.04%$104,090102.0K
39NYXOAH SASHS0.03%$80,38916.1K
40HUMAHUMACYTE INC*W EXP 08/27/2020.01%$20,31450.0K
41NEOLEUKIN THERAPEUTICS INCCOM0.01%$19,50138.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$697M76May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$636M68Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$395M51Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$262M52Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$336M54May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$355M51Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$252M39Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$370M48Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$336M51May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$439M43Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$323M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$393M47Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$202M44May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$270M47Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$315M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$266M62Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$302M66May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$332M70Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$314M61Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$402M74Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$493M89May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$489M89Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$505M89Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$343M78Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$298M69May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$420M69Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$310M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$415M71Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$370M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$275M69Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.